Applied pharmacology in percutaneous coronary intervention: You can't fight mother nature

• Differential outcomes based on target vessel diameter persist in the era of second generation drug eluting stents.
• These differences are mainly driven by need for target vessel revascularization without appreciable differences in hard atherosclerotic cardiovascular disease outcomes that is, mortality and myocardial infarction.
• Future non mechanistic treatment options based on patient characteristics maybe needed.